Semaglutide dose for weight loss: what real-world reviews reveal about each step

Step 1: the 0.25 mg starting dose and what reviewers say about it

Almost every dose review starts with mild disappointment. At 0.25 mg, appetite suppression is subtle. Many people notice a slight reduction in hunger, but the dramatic effect they expected does not arrive yet. This is deliberate: the starter dose is there to settle your digestive system into the medicine, not to deliver measurable weight loss. Prescribers follow this schedule specifically to reduce early nausea.

The most commonly reported experience at this stage is mild nausea after injection day, occasional burping, and a modest drop in appetite by the end of the week. On the whole, people describe it as manageable. A quick practical check worth doing at this stage: note the injection day in your calendar and track any symptoms in the 48 hours that follow. A pattern usually becomes clear within two or three weeks, and it is useful information if you speak to your prescriber.

If you want a detailed breakdown of what the 0.25 mg stage involves, early-dose Wegovy reviews cover this period in more depth. The short version from most accounts: stick with it.

Steps 2 and 3: the 0.5 mg and 1.0 mg doses, where appetite suppression becomes noticeable

Reviews consistently identify the 0.5 mg to 1.0 mg range as the point where something shifts. Appetite drops more clearly. Portion sizes shrink without effort. Some people describe this as the first time food stops being a constant background thought. It is also where gastrointestinal side effects can intensify temporarily after each increase, nausea, constipation or looser stools are the ones mentioned most often, and they tend to ease within a week or two.

The 1.0 mg dose stage gets a mixed reception in reviews. A portion of people find this dose already effective enough that they question whether to increase further. Others find the effect levels off after a few weeks. NICE guidance and the prescribing schedule are clear that titration continues to the maintenance dose unless a clinical reason to stop exists, so the decision is a prescriber's rather than the patient's to make unilaterally.

The NHS medicines information for semaglutide covers side effects across the schedule and is worth reading at each stage, find it via the NHS semaglutide page.

Steps 4 and 5: 1.7 mg and 2.4 mg, and what the evidence says about results

The 1.7 mg step is often described in reviews as quieter than the earlier increases. By now most people have adapted to the medicine, and the jump from 1.0 mg to 1.7 mg is proportionally smaller than previous steps. The 2.4 mg maintenance dose is where the bulk of clinical evidence is anchored. In the STEP 1 trial, participants on 2.4 mg lost an average of around 15% of their body weight over 68 weeks alongside lifestyle changes.

Reviews at this stage split into two camps. One group reports consistent, ongoing weight loss with modest ongoing side effects. A second group hits a plateau and wonders what comes next. For them, the newer 7.2 mg formulation (approved by the MHRA in January and April 2026) extends the ceiling. The full Wegovy dose overview covers the 7.2 mg pathway in detail, including what the approval means practically.

One thing reviewers at 2.4 mg agree on: the medicine works best alongside consistent food and activity habits. Semaglutide reduces appetite; it does not override food choices entirely. If you are earlier in the schedule and want to understand what the 2.5 Wegovy pen involves before you reach that point, it is worth reading up ahead of your next prescriber review. For cost context at this stage of treatment, the Wegovy cost page gives a transparent picture of what private treatment involves at each dose level.

What reviews get wrong, and what to take from them

The most useful thing to know about semaglutide dose reviews is their selection bias. People who had a difficult early experience are more likely to write something online. People who had an unremarkable, effective course often do not. This skews public perception toward side effects and away from the steady, undramatic progress that many people describe privately to their prescribers.

Reviews also rarely mention that semaglutide is a prescription-only medicine requiring clinical assessment before each stage of treatment. The dose you are on at any given time is not a personal choice to optimise by reading forums, it is a clinical one, reviewed at each repeat. At nume, a GPhC-registered prescriber personally reviews every consultation and every repeat order. There is no algorithm making that call.

If you are weighing up the injection against the newer oral option, the semaglutide dose overview covers both formats side by side. And if you are curious whether semaglutide or tirzepatide suits your situation better, our treatment overview lays out the options clearly. When you are ready to see whether you are clinically suitable, starting a free consultation is the first step, a prescriber reviews your answers the same day.